B0F Stock Chart & Stats
€5.00
-€0.16(-3.65%)
At close: 4:00 PM EDT
€5.00
-€0.16(-3.65%)
Day’s Range― - ―
52-Week Range€3.78 - €6.10
Previous CloseN/A
Volume0.00
Average Volume (3M)83.00
Market Cap
€140.14M
Enterprise Value€1.06B
Total Cash (Recent Filing)€105.64M
Total Debt (Recent Filing)€12.37M
Price to Earnings (P/E)―
Beta0.22
Next Earnings
Nov 20, 2026EPS Estimate
0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding23,273,417
10 Day Avg. Volume0
30 Day Avg. Volume83
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)3.05
Price to Sales (P/S)3.95
P/FCF Ratio-76.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.17
Revenue Forecast (FY)€37.47M
Bulls Say, Bears Say
Bulls Say
Strong Commercial GrowthRapid sales growth indicates expanding adoption of Paxman’s scalp-cooling systems and stronger commercial execution. If sustained, higher revenue can broaden the installed base, increase treatment-related recurring income, and improve operating leverage as the business scales.
Recurring IBBM Utilization GrowthThe sharp increase in insurance-based billing supports a more repeatable revenue model tied to patient treatments rather than only equipment placements. Higher utilization can deepen site economics, encourage broader clinic adoption, and increase recurring revenue from the installed base.
Conservative Balance SheetVery low leverage reduces financial risk and preserves flexibility to fund commercial expansion, product development, and customer installations without substantial debt-service pressure. A conservative capital structure also gives Paxman greater resilience if profitability or cash generation remains uneven.
Bears Say
Recent Return To LossesThe return to a net loss weakens the immediate earnings foundation despite strong revenue momentum. Near-break-even operating profit leaves limited room for cost increases or execution setbacks, while sustained losses could constrain reinvestment and reduce the durability of reported growth.
Negative Cash GenerationNegative operating and free cash flow indicate that current operations are not yet funding reinvestment and working-capital needs internally. If this persists alongside losses, Paxman may need to rely more heavily on existing liquidity or external funding to support expansion.
Neuropathy-device Regulatory DelayThe De Novo pathway delays potential commercialization of the neuropathy device and introduces greater approval uncertainty than the planned 510(k) route. Additional information or clinical-data requests could extend timing further, postponing a potentially important product and revenue opportunity.
Paxman AB News
B0F FAQ
What was Paxman AB’s price range in the past 12 months?
Paxman AB lowest stock price was €3.77 and its highest was €6.10 in the past 12 months.
What is Paxman AB’s market cap?
Paxman AB’s market cap is €140.14M.
When is Paxman AB’s upcoming earnings report date?
Paxman AB’s upcoming earnings report date is Nov 20, 2026 which is in 20 days.
How were Paxman AB’s earnings last quarter?
Paxman AB released its earnings results on Aug 21, 2026. The company reported €0.009 earnings per share for the quarter, missing the consensus estimate of €0.027 by -€0.018.
Is Paxman AB overvalued?
According to Wall Street analysts Paxman AB’s price is currently Overvalued.
Does Paxman AB pay dividends?
Paxman AB does not currently pay dividends.
What is Paxman AB’s EPS estimate?
Paxman AB’s EPS estimate is 0.04.
How many shares outstanding does Paxman AB have?
Paxman AB has 23,273,417 shares outstanding.
What happened to Paxman AB’s price movement after its last earnings report?
Paxman AB reported an EPS of €0.009 in its last earnings report, missing expectations of €0.027. Following the earnings report the stock price went up 17.968%.
Which hedge fund is a major shareholder of Paxman AB?
Currently, no hedge funds are holding shares in DE:B0F
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Paxman AB
Paxman AB (publ), along with its subsidiaries, specializes in the creation and worldwide sale of the Paxman scalp cooling system, an innovative solution designed to minimize hair loss in patients undergoing chemotherapy. This system is distributed across Europe, the United States, Mexico, Japan, Oceania, various Asian regions, and both South and Central America, primarily serving cancer centers and hospitals. The company is also engaged in a research collaboration agreement with the National University Hospital in Singapore, working towards the development of a portable cooling and compression device. Established in 1996, Paxman AB (publ) is headquartered in Karlshamn, Sweden.
B0F Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights strong commercial momentum: record quarterly sales (+40% YoY), substantial U.S. revenue growth (~+77.5% YoY), large increases in insurance-based billing (110%), improved adjusted margins (~19%), a robust order book (190 systems, 80 in U.S.), and a healthy cash position (SEK 105m). These positives are tempered by a regulatory setback for the neuropathy device (shift to De Novo with an 8–12 month review window), increased operating and CIPN-related costs (OpEx up ~SEK 6m q/q; CIPN costs up ~30%), and a slower near-term U.S. rollout for CIPN. Overall, company fundamentals and commercial traction are strong and appear to outweigh the regulatory and cost challenges, but the De Novo timeline introduces meaningful near-term uncertainty for the new product launch.View all DE:B0F earnings summariesTechnical Analysis
Senzime AB
―
Xvivo Perfusion AB
―
Bactiguard Holding AB
―
BrainCool AB
―
Sedana Medical AB
―